Minafra L.,CNR Institute of Neuroscience |
Minafra L.,Laboratorio Of Tecnologie Oncologiche Lato Hsr Ggiglio |
Norata R.,Laboratorio Of Tecnologie Oncologiche Lato Hsr Ggiglio |
Bravata V.,CNR Institute of Neuroscience |
And 9 more authors.
BMC Research Notes | Year: 2012
Background: Immortalized cancer cell lines are now well-established procedures in biomedicine for a more complete understanding of cellular processes in cancer. However, they are more useful in preparation of fresh tumour tissue, in order to obtain cancer cells with highly preserved individual tumour properties. In the present study we report an analytical investigation on a breast cancer primary cell culture isolated from a surgical specimen obtained from a patient with an infiltrating ductal carcinoma. The objective of the research was to reveal unrecognized aspects of neoplastic cells, typical of the tumour from where the cells were derived, but masked in fixed tissue sections, in order to better predict the aggressive potentiality of the tumour. Findings. Using a combination of mechanical and enzymatic treatment, the tumour tissue was dissociated immediately after surgical removal. The primary cells were isolated by differential cell centrifugation and grown in selective media. Immunocytochemistry and quantitative RT-PCR analysis were performed to detect the presence of specific biomarkers at protein and transcript level. The isolated primary breast cancer cells displayed phenotypic behaviour, characteristic of malignant cells and expression of several mesenchymal markers, revealing a strong signature for the epithelial-to-mesenchymal transition associated to a stellate morphology with a number of cellular protrusions and the attitude to overgrow as multilayered overlapping cellular foci. Conclusions: Our data are a further meaningful indication that primary cell cultures represent a powerful system that could be applied to those cases deserving a deeper investigation at molecular level in order to design individualized anticancer therapies in the future. © 2012 Minafra et al.; licensee BioMed Central Ltd. Source
Candiano G.,Laboratorio Of Tecnologie Oncologiche Lato Hsr Ggiglio |
Russo G.,Laboratorio Of Tecnologie Oncologiche Lato Hsr Ggiglio |
Russo G.,CNR Institute of Neuroscience |
Stefano A.,Laboratorio Of Tecnologie Oncologiche Lato Hsr Ggiglio |
And 12 more authors.
AIP Conference Proceedings | Year: 2012
Aim of the present study is to evaluate the efficacy of the Magnetic Resonance guided Focused Ultrasound (Insightec ExAblate 2000 system) in a clinical case of a pelvic bone metastasis, accessible to the ultrasonic beam. Multiple 18F-FDG PET/CT examinations allowed to follow the metabolic and morphological modification of the cancerous lesion. © 2012 American Institute of Physics. Source
Bravata V.,CNR Institute of Molecular Bioimaging and Physiology |
Bravata V.,Laboratorio Of Tecnologie Oncologiche Lato Hsr Ggiglio |
Cammarata F.P.,CNR Institute of Molecular Bioimaging and Physiology |
Cammarata F.P.,Laboratorio Of Tecnologie Oncologiche Lato Hsr Ggiglio |
And 4 more authors.
OMICS A Journal of Integrative Biology | Year: 2013
HER2/neu amplification/overexpression is the only somatic mutation widely considered to be a marker of disease outcome and response to treatment in breast cancer. Pathologists have made large efforts to achieve accuracy in characterizing HER2/neu status. The introduction of transtuzumab contributed to development of additional measures to identify sensitive and resistant subclasses of HER2/neu-positive tumors. In this article, we describe the latest advances in HER2/neu status diagnostic assessment and the most relevant research emerging from "Omics" (genomics, epigenetics, transcriptomics, and proteomics) studies on HER2/neu-positive breast cancer. A large quantity of biomarkers from different studies highlighted HER2/neu-positive specific proliferation, cell cycle arrest, and apoptosis mechanisms, as well as immunological and metabolic behavior. Major driver genes of tumor progression have had a candidate status (GRB7, MYC, CCND1, EGFR, etc.), even though the main role for HER2/neu is largely recognized. Nonetheless, existing omics data and HER2/neu-positive molecular profiles seem to suggest that few proteogenomic alterations in HER2, EGFR, and PI3K networks could significantly affect the effectiveness of transtuzumab. The systematic search of molecular alterations in and across these pathways can help to select the most appropriate drug for a given patient based on in-depth understanding of complexity in tumor biology. © 2013, Mary Ann Liebert, Inc. Source